TransMedics Group, Inc. (NASDAQ:TMDX) Stock Has Consensus Target Price of $121.10 According to Analysts

Shares of TransMedics Group, Inc. (NASDAQ:TMDX) have been assigned an average rating of “Hold” from the thirteen brokerages that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, six have issued a hold recommendation and six have assigned a buy recommendation to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $121.00.

Several brokerages recently commented on TMDX. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $124.00 price objective on shares of TransMedics Group in a research report on Tuesday, June 30th. UBS Group dropped their target price on shares of TransMedics Group from $80.00 to $77.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 5th. Needham & Company LLC reissued a “buy” rating on shares of TransMedics Group in a research report on Friday, September 11th. Zacks Research lowered shares of TransMedics Group from a “hold” rating to a “strong sell” rating in a research note on Monday, July 6th. Finally, Weiss Ratings raised shares of TransMedics Group from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, August 31st.

Insider Activity at TransMedics Group

In related news, Director David Weill acquired 1,336 shares of the company’s stock in a transaction dated Friday, September 11th. The shares were purchased at an average cost of $81.63 per share, with a total value of $109,057.68. Following the completion of the acquisition, the director directly owned 16,392 shares of the company’s stock, valued at $1,338,078.96. This represents a 8.87% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 6.90% of the company’s stock.

Hedge Funds Weigh In On TransMedics Group

Several hedge funds have recently made changes to their positions in TMDX. Goldman Sachs Group Inc. grew its stake in TransMedics Group by 50.1% during the 4th quarter. Goldman Sachs Group Inc. now owns 965,931 shares of the company’s stock valued at $117,506,000 after purchasing an additional 322,353 shares during the last quarter. Braidwell LP increased its holdings in shares of TransMedics Group by 85.1% in the second quarter. Braidwell LP now owns 609,715 shares of the company’s stock valued at $40,497,000 after purchasing an additional 280,324 shares during the period. Deutsche Bank AG acquired a new position in shares of TransMedics Group in the second quarter valued at about $14,415,000. Bank of New York Mellon Corp purchased a new position in shares of TransMedics Group in the second quarter worth about $12,869,000. Finally, Legal & General Group Plc purchased a new position in shares of TransMedics Group in the second quarter worth about $5,286,000. 99.67% of the stock is owned by institutional investors and hedge funds.

TransMedics Group Stock Performance

Shares of TMDX stock opened at $77.87 on Monday. TransMedics Group has a 12-month low of $60.10 and a 12-month high of $156.00. The business’s fifty day simple moving average is $86.01 and its 200-day simple moving average is $83.73. The company has a current ratio of 6.62, a quick ratio of 6.07 and a debt-to-equity ratio of 1.62. The company has a market cap of $2.69 billion, a PE ratio of 20.02, a PEG ratio of 1.07 and a beta of 1.94.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings results on Tuesday, August 4th. The company reported $0.44 EPS for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.06). TransMedics Group had a net margin of 22.69% and a return on equity of 15.88%. The business had revenue of $189.95 million during the quarter, compared to analysts’ expectations of $184.00 million. During the same quarter last year, the business posted $0.92 earnings per share. The company’s quarterly revenue was up 20.7% compared to the same quarter last year. Analysts expect that TransMedics Group will post 1.46 earnings per share for the current fiscal year.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical technology company that develops organ transplant systems designed to preserve and assess donated organs outside the body before transplantation. Its primary platform, the Organ Care System (OCS), uses warm perfusion technology to circulate oxygenated blood and nutrients through organs, helping maintain organ function during transport and potentially expanding the pool of organs available for transplant.

The company offers OCS solutions for heart, lung and liver transplantation.